Solid Tumor Cancer PBMC

About Solid Tumor Cancer PBMC

Solid Tumor Cancer PBMC for Immuno-Oncology Research

Solid Tumor Cancer PBMC samples are collected from IRB-consented donors clinically diagnosed with solid-tumour cancers, processed within 24 hours of collection and preserved in CryoStor® CS10 to maintain viability and function. These cryopreserved peripheral blood mononuclear cells support study of tumour-immune interactions, immune-checkpoint regulation and systemic immune responses across a range of solid tumours, in cell counts from 5 million to 2 billion.

Why Solid Tumour PBMC for Immuno-Oncology Research

Solid tumours are neoplastic diseases, and the peripheral immune compartment of a cancer patient is systematically different from that of a healthy donor. Tumours shape host immunity through secreted factors, chronic antigen exposure and expansion of suppressive cell populations, and those changes are detectable in circulating mononuclear cells. Healthy-donor PBMCs cannot reproduce this state, which is why disease-state cells matter for immuno-oncology assay development.

• T-cell exhaustion — chronic tumour antigen exposure drives inhibitory receptor expression including PD-1, TIM-3, LAG-3 and TIGIT, with reduced proliferative and cytotoxic capacity.
• Suppressive myeloid expansion — myeloid-derived suppressor cells expand in the circulation of cancer patients and actively inhibit T-cell function, making them both a confounder and a target.
• Regulatory T-cell expansion — increased Treg frequency and suppressive capacity contribute to peripheral tolerance of the tumour.
• Immune-checkpoint axis — PD-1 and CTLA-4 expression on donor T cells is the direct substrate for checkpoint-inhibitor mechanism-of-action and potency work.
• NK cell and effector function — cytotoxicity and antibody-dependent cellular cytotoxicity capacity in patient-derived effectors is the realistic setting for antibody and engager potency assays.
• Cellular specimen advantage — because PBMCs are viable nucleated cells, flow cytometry, killing and suppression assays, antigen-specific stimulation, single-cell transcriptomics and TCR repertoire sequencing are all available; none are possible in an acellular plasma or serum product.

Donor Stratification Available

• Tumour indication — breast, lung, colorectal, pancreatic, prostate, ovarian, renal and other solid tumours, subject to availability
• Stage and disease extent — localised, locally advanced, and metastatic disease
• Treatment status — treatment-naive, on immune-checkpoint inhibitor therapy, on chemotherapy or targeted therapy, and post-treatment donors
• Response and trajectory — responding versus progressing donors; serial draws from the same donor where collected
• Molecular and biomarker context — indication-specific markers such as HER2, hormone receptor, EGFR/ALK or microsatellite status where documented
• Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity

Product Features

• Research Use Only (RUO), cryopreserved solid-tumour PBMC samples
• Clinically confirmed solid-tumour cancer donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Preserved using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screening (LeukoLot™) available prior to bulk orders

De-identified Donor Data

• Verified solid-tumour cancer diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Indication, stage and treatment context reported per lot where captured
• Additional tumour-type and clinical data available on request

Applications

• T-cell exhaustion and inhibitory receptor immunophenotyping
• Immune-checkpoint inhibitor mechanism-of-action and potency assays
• Myeloid-derived suppressor cell and regulatory T-cell characterisation and suppression assays
• NK cell cytotoxicity and antibody-dependent cellular cytotoxicity assays
• Patient-derived effector cell sourcing for bispecific engager and CAR construct potency work
• Single-cell transcriptomic and TCR repertoire profiling in cancer cohorts
• Drug screening and ex vivo pharmacology in disease-state immune cells
• Biomarker discovery and validation for response and resistance to immunotherapy

Other Solid Tumor Cancer Specimen Types

• Solid Tumor Cancer Plasma
• Solid Tumor Cancer Serum
• Solid Tumor Cancer Whole Blood
• Solid Tumor Cancer Leukopak

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent
• HIPAA-compliant donor data protection

Ordering & Customization

Solid Tumor Cancer PBMC samples ship on dry ice in standard or custom aliquots. For pricing, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To compare collection formats, browse all human PBMCs or request a custom disease-state collection.